PNC Financial Services Group’s Lexeo Therapeutics LXEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.93K Buy
570
+336
+144% +$1.52K ﹤0.01% 4848
2026
Q2
$1.09K Sell
234
-271
-54% -$1.47K ﹤0.01% 4821
2026
Q1
$2.9K Buy
505
+18
+4% +$128 ﹤0.01% 4469
2025
Q4
$4.84K Sell
487
-186
-28% -$1.7K ﹤0.01% 4245
2025
Q3
$4.47K Buy
+673
New +$3.26K ﹤0.01% 4246

Other funds holding LXEO

PNC Financial Services Group's LXEO Position: Q3 2026 in Review

PNC Financial Services Group increased its Lexeo Therapeutics (LXEO) stake by 144% in Q3 2026, buying an estimated $1.52K and bringing the position to 570 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #4848.

PNC Financial Services Group first reported a position in LXEO in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.84K in Q4 2025. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • PNC Financial Services Group held 570 shares of Lexeo Therapeutics worth $1.93K as of Q3 2026.
  • PNC Financial Services Group bought 336 Lexeo Therapeutics shares in Q3 2026, an estimated $1.52K.
  • Lexeo Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4848 holding.
  • PNC Financial Services Group first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • PNC Financial Services Group's Lexeo Therapeutics position peaked at $4.84K in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.